Amazon's AWS sees 20% growth driven by surging AI demand, investing billions to expand cloud infrastructure.
Moderna halts development of its experimental CMV vaccine after Phase III trial fails to meet primary endpoint, leaving the field without an approved congenital CMV vaccine.
Globe Life reports strong Q3 results driven by growth in life and health insurance underwriting, maintaining its position as a reliable investment in the financial sector.
Amazon's AWS sees 20% growth driven by surging AI demand, investing billions to expand cloud infrastructure.
Moderna halts development of its experimental CMV vaccine after Phase III trial fails to meet primary endpoint, leaving the field without an approved congenital CMV vaccine.
Globe Life reports strong Q3 results driven by growth in life and health insurance underwriting, maintaining its position as a reliable investment in the financial sector.